致癌基因 reg IV 是一种新的胶质母细胞瘤患者生存预后标志物。
Oncogenic reg IV is a novel prognostic marker for glioma patient survival.
机构信息
Department of Experimental Surgery, Tangdu Hospital, Fourth Military Medical University, Xi'an City 710032, China.
出版信息
Diagn Pathol. 2012 Jun 19;7:69. doi: 10.1186/1746-1596-7-69.
AIM
The aberrant expression of regenerating islet-derived family member, 4 (Reg IV) has been found in various human cancers. However, the roles of Reg IV gene and its encoding product in human glioma have not been clearly understood. Therefore, the aim of this study was to investigate the clinicopathological significance of Reg IV expression in glioma.
METHODS
Reg IV mRNA and protein expression in human gliomas and non-neoplastic brain tissues were respectively detected by real-time quantitative RT-PCR assay, Western blot, and immunohistochemistry. The association of Reg IV immunostaining with clinicopathological factors and prognosis of glioma patients was also statistically analyzed.
RESULTS
Reg IV mRNA and protein expression levels in glioma tissues were both significantly higher than those in the corresponding non-neoplastic brain tissues (both P < 0.001). Additionally, the increased Reg IV immunostaining in glioma tissues was significantly associated with advanced pathological grade (P = 0.008). Reg IV protein up-regulation was also significantly correlated with low Karnofsky performance score (KPS) (P = 0.02). Moreover, the overall survival of patients with high Reg IV protein expression was dramatically shorter than those with low Reg IV protein expression (P < 0.001). Multivariate Cox regression analysis further confirmed that Reg IV expression was an independent prognostic factor for patients with gliomas (P = 0.008).
CONCLUSIONS
These convinced evidences suggest for the first time that Reg IV might accelerate disease progression and act as a candidate prognostic marker for gliomas.
VIRTUAL SLIDES
The virtual slide(s) for this article can be found here:http://www.diagnosticpathology.diagnomx.eu/vs/2145344361720706.
目的
再生胰岛衍生家族成员 4（Reg IV）的异常表达已在各种人类癌症中发现。然而，Reg IV 基因及其编码产物在人类神经胶质瘤中的作用尚未明确。因此，本研究旨在探讨 Reg IV 表达在神经胶质瘤中的临床病理意义。
方法
采用实时定量 RT-PCR 检测、Western blot 和免疫组织化学方法分别检测人脑胶质瘤和非神经组织中 Reg IV mRNA 和蛋白的表达。统计学分析 Reg IV 免疫染色与神经胶质瘤患者临床病理因素和预后的关系。
结果
神经胶质瘤组织中 Reg IV mRNA 和蛋白表达水平均明显高于相应的非神经组织（均 P<0.001）。此外，神经胶质瘤组织中 Reg IV 免疫染色的增加与高级别病理分级显著相关（P=0.008）。Reg IV 蛋白的上调与 Karnofsky 表现评分低（P=0.02）显著相关。此外，Reg IV 蛋白高表达患者的总生存期明显短于 Reg IV 蛋白低表达患者（P<0.001）。多因素 Cox 回归分析进一步证实，Reg IV 表达是神经胶质瘤患者的独立预后因素（P=0.008）。
结论
这些令人信服的证据首次表明，Reg IV 可能加速疾病进展，并可作为神经胶质瘤的候选预后标志物。
Zotero 插件